Barbara LeBlanc

769 total citations
45 papers, 629 citations indexed

About

Barbara LeBlanc is a scholar working on Pharmacology, Molecular Medicine and Oncology. According to data from OpenAlex, Barbara LeBlanc has authored 45 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pharmacology, 23 papers in Molecular Medicine and 18 papers in Oncology. Recurrent topics in Barbara LeBlanc's work include Antibiotics Pharmacokinetics and Efficacy (24 papers), Antibiotic Resistance in Bacteria (23 papers) and Neutropenia and Cancer Infections (16 papers). Barbara LeBlanc is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (24 papers), Antibiotic Resistance in Bacteria (23 papers) and Neutropenia and Cancer Infections (16 papers). Barbara LeBlanc collaborates with scholars based in United States and Canada. Barbara LeBlanc's co-authors include Gerald P. Bodey, D H Ho, Kenneth V. I. Rolston, Victor Fainstein, K. V. I. Rolston, Susan Frisbee‐Hume, Linda S. Elting, Kenneth Rolston, Kalen Jacobson and Estella Whimbey and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Clinical Pharmacology & Therapeutics and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Barbara LeBlanc

43 papers receiving 507 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barbara LeBlanc United States 15 364 305 177 131 124 45 629
Axel Dalhoff Germany 13 250 0.7× 348 1.1× 248 1.4× 116 0.9× 74 0.6× 24 780
M. Husson Belgium 13 205 0.6× 176 0.6× 165 0.9× 175 1.3× 96 0.8× 35 499
Barbara G. Painter United States 14 292 0.8× 197 0.6× 253 1.4× 229 1.7× 213 1.7× 24 800
J. Mohler France 13 158 0.4× 147 0.5× 153 0.9× 133 1.0× 70 0.6× 31 539
C E Fasching United States 14 225 0.6× 181 0.6× 195 1.1× 125 1.0× 94 0.8× 22 575
M. J. Bywater United Kingdom 16 337 0.9× 228 0.7× 159 0.9× 74 0.6× 81 0.7× 33 558
B Kolek United States 13 307 0.8× 294 1.0× 206 1.2× 173 1.3× 89 0.7× 16 637
P. Acred United Kingdom 14 311 0.9× 236 0.8× 160 0.9× 145 1.1× 70 0.6× 30 675
E Huczko United States 15 345 0.9× 273 0.9× 356 2.0× 317 2.4× 86 0.7× 20 806
Carlos I. Bustamante United States 15 356 1.0× 226 0.7× 238 1.3× 106 0.8× 106 0.9× 21 654

Countries citing papers authored by Barbara LeBlanc

Since Specialization
Citations

This map shows the geographic impact of Barbara LeBlanc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara LeBlanc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara LeBlanc more than expected).

Fields of papers citing papers by Barbara LeBlanc

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara LeBlanc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara LeBlanc. The network helps show where Barbara LeBlanc may publish in the future.

Co-authorship network of co-authors of Barbara LeBlanc

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara LeBlanc. A scholar is included among the top collaborators of Barbara LeBlanc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara LeBlanc. Barbara LeBlanc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rolston, Kenneth V. I., et al.. (2004). In vitro Antimicrobial Activity of Gatifloxacin Compared with Other Quinolones against Clinical Isolates from Cancer Patients. Chemotherapy. 50(5). 214–220. 11 indexed citations
2.
Rolston, Kenneth V. I., et al.. (2003). In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagnostic Microbiology and Infectious Disease. 47(2). 441–449. 24 indexed citations
3.
Rolston, Kenneth V. I., et al.. (2002). In vitro activity of ertapenem against bacterial isolates from cancer patients. Diagnostic Microbiology and Infectious Disease. 43(3). 219–223. 12 indexed citations
4.
Rolston, Kenneth V. I., et al.. (2002). Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients. Diagnostic Microbiology and Infectious Disease. 44(2). 187–194. 17 indexed citations
5.
Jacobson, Kalen, Kenneth V. I. Rolston, Linda S. Elting, et al.. (1999). Susceptibility Surveillance among Gram-Negative Bacilli at a Cancer Center. Chemotherapy. 45(5). 325–334. 39 indexed citations
6.
Rolston, K. V. I., et al.. (1996). In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against Gram-positive clinical isolates from cancer patients. Journal of Antimicrobial Chemotherapy. 38(2). 265–269. 18 indexed citations
7.
Rolston, K. V. I., et al.. (1991). In vitro activity of cefpodoxime against bacterial isolates obtained from patients with cancer. European Journal of Clinical Microbiology & Infectious Diseases. 10(7). 581–585. 1 indexed citations
8.
Rolston, Kenneth V. I., et al.. (1990). In vitro Activity of PD 127,391, a New Quinolone against Bacterial Isolates from Cancer Patients. Chemotherapy. 36(5). 365–372. 2 indexed citations
9.
Rolston, Kenneth V. I., et al.. (1990). In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients. Journal of Antimicrobial Chemotherapy. 26(1). 39–44. 11 indexed citations
10.
Rolston, Kenneth V. I., et al.. (1989). In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients. Journal of Antimicrobial Chemotherapy. 23(3). 363–371. 7 indexed citations
11.
Rolston, Kenneth, D H Ho, Barbara LeBlanc, & Gerald P. Bodey. (1988). Comparative in vitro activity of the two new 4-quinolones S-25930 and S-25932 against gram-positive bacteria isolated from cancer patients. European Journal of Clinical Microbiology & Infectious Diseases. 7(5). 681–683. 2 indexed citations
12.
Rolston, Kenneth V. I., D H Ho, Barbara LeBlanc, & Gerald P. Bodey. (1988). In vitro Activity of Fleroxacin (Ro23-6240), a New Fluorinated 4-Quinolone against Isolates from Cancer Patients. Chemotherapy. 34(6). 448–454. 3 indexed citations
13.
Rolston, K. V. I., et al.. (1988). Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients. European Journal of Clinical Microbiology & Infectious Diseases. 7(5). 684–686. 20 indexed citations
14.
Rolston, Kenneth V. I., et al.. (1987). In vitro Evaluation of Difloxacin (A-56619), A-56620, and Other 4-Quinolones against Isolates from Cancer Patients. Chemotherapy. 33(6). 419–427. 2 indexed citations
15.
Saito, Hiroshi, Kenneth V. I. Rolston, D H Ho, Barbara LeBlanc, & Gerald P. Bodey. (1987). In-vitro activity of LY146032 against Gram-positive isolates from cancer patients. Journal of Antimicrobial Chemotherapy. 20(4). 497–503. 2 indexed citations
16.
Rolston, K. V. I., Barbara LeBlanc, D H Ho, & Gerald P. Bodey. (1987). In vitro activity of paldimycin (U-70138F) against gram-positive bacteria isolated from patients with cancer. Antimicrobial Agents and Chemotherapy. 31(4). 650–652. 5 indexed citations
17.
Rolston, Kenneth, D H Ho, Barbara LeBlanc, & Gerald P. Bodey. (1986). Activity of newer antimicrobial agents againstAeromonas hydrophila. European Journal of Clinical Microbiology & Infectious Diseases. 5(4). 454–456. 11 indexed citations
18.
LeBlanc, Barbara. (1985). Les Interdictions sur la Danse au Canada Francais. 13. 1 indexed citations
19.
LeBlanc, Barbara, et al.. (1979). BL-S786 (Ceforanide), a New Parenteral Cephalosporin: In Vitro Studies. Antimicrobial Agents and Chemotherapy. 15(2). 318–322. 18 indexed citations
20.
Bodey, Gerald P., et al.. (1977). In Vitro Studies of Netilmicin, a New Aminoglycoside Antibiotic. Antimicrobial Agents and Chemotherapy. 11(6). 1017–1020. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Axel Dalhoff Breakdown of academic impact, for papers by M. Husson Breakdown of academic impact, for papers by Barbara G. Painter Breakdown of academic impact, for papers by J. Mohler Breakdown of academic impact, for papers by C E Fasching Breakdown of academic impact, for papers by M. J. Bywater Breakdown of academic impact, for papers by B Kolek Breakdown of academic impact, for papers by P. Acred Breakdown of academic impact, for papers by E Huczko Breakdown of academic impact, for papers by Carlos I. Bustamante
Rankless by CCL
2026